Table 1. Cox-proportional hazards regression analyses of UCK2 gene expression and breast cancer survival in 10 public microarray datasets.
| Dataset accession No. | Category | Overall survival | Disease-free survival | ||
|---|---|---|---|---|---|
| HR (95% CI) | Adjusted HR (95% CI)* | HR (95% CI) | Adjusted HR (95% CI)* | ||
| GSE1456 | Q1 | Ref. | Ref. | Ref. | Ref. |
| Q2 | 1.58 (0.53–5.24) | 1.88 (0.58–7.13) | 1.98 (0.62–7.41) | 2.03 (0.63–7.69) | |
| Q3 | 2.59 (0.96–8.17) | 1.80 (0.56–6.87) | 3.32 (1.16–11.89) | 2.13 (0.69–7.93) | |
| Q4 | 3.20 (1.24–9.83) | 2.97 (1.02–10.77) | 4.42 (1.62–15.45) | 3.04 (1.06–10.96) | |
| GSE2034 | Q1 | Ref. | Ref. | Ref. | Ref. |
| Q2 | NA | NA | 1.37 (0.81–2.36) | 1.37 (0.81–2.36) | |
| Q3 | NA | NA | 1.01 (0.56–1.79) | 1.01 (0.56–1.81) | |
| Q4 | NA | NA | 1.46 (0.84–2.52) | 1.47 (0.84–2.61) | |
| GSE4922 | Q1 | Ref. | Ref. | Ref. | Ref. |
| Q2 | NA | NA | 0.99 (0.54–1.83) | 0.86 (0.46–1.59) | |
| Q3 | NA | NA | 1.17 (0.64–2.16) | 0.95 (0.50–1.80) | |
| Q4 | NA | NA | 1.31 (0.73–2.38) | 0.89 (0.47–1.68) | |
| GSE7390 | Q1 | Ref. | Ref. | Ref. | Ref. |
| Q2 | 1.23 (0.55–2.73) | 1.11 (0.50–2.48) | 1.87 (1.04–3.45) | 1.79 (0.99–3.30) | |
| Q3 | 1.27 (0.58–2.79) | 0.95 (0.43–2.16) | 1.25 (0.67–2.36) | 1.10 (0.58–2.11) | |
| Q4 | 1.59 (0.76–3.41) | 1.40 (0.63–3.19) | 1.39 (0.74–2.63) | 1.20 (0.61–2.38) | |
| GSE10885 | Q1 | Ref. | Ref. | Ref. | Ref. |
| Q2 | 2.25 (0.81–7.17) | 2.52 (0.78–9.68) | 1.55 (0.71–3.54) | 1.29 (0.53–3.23) | |
| Q3 | 3.91 (1.48–12.18) | 3.47 (1.16–12.95)† | 1.93 (0.87–4.46) | 1.49 (0.62–3.82) | |
| Q4 | 3.84 (1.52–11.65) | 3.02 (0.94–12.00) | 2.14 (1.01–4.81) | 1.36 (0.53–3.71) | |
| GSE 22226 | Q1 | Ref. | Ref. | Ref. | Ref. |
| Q2 | 1.32 (0.48–3.61) | 1.19 (0.40–3.52) | 1.07 (0.40–2.92) | 0.99 (0.34–2.91) | |
| Q3 | 1.23 (0.43–3.45) | 0.94 (0.29–2.97) | 0.92 (0.32–2.56) | 0.72 (0.23–2.22) | |
| Q4 | 3.32 (1.45–8.26) | 2.41 (0.89–7.06) | 2.76 (1.22–6.80) | 1.95 (0.75–5.51) | |
| GSE24450 | Q1 | Ref. | Ref. | Ref. | Ref. |
| Q2 | 0.53 (0.11–2.15) | NA | 0.44 (0.09–1.68) | NA | |
| Q3 | 2.28 (0.85–7.19) | NA | 1.87 (0.71–5.43) | NA | |
| Q4 | 3.48 (1.37–10.61) | NA | 3.60 (1.52–9.90)‡ | NA | |
| GSE25066 | Q1 | Ref. | Ref. | Ref. | Ref. |
| Q2 | NA | NA | 0.73 (0.26–1.96) | 0.61 (0.22–1.66) | |
| Q3 | NA | NA | 1.60 (0.70–3.83) | 1.38 (0.58–3.41) | |
| Q4 | NA | NA | 1.76 (0.78–4.19) | 0.90 (0.36–2.35) | |
| GSE53031 | Q1 | Ref. | Ref. | Ref. | Ref. |
| Q2 | NA | NA | 0.95 (0.57–1.59) | 0.93 (0.53–1.62) | |
| Q3 | NA | NA | 1.54 (0.93–2.55) | 1.69 (0.95–3.00) | |
| Q4 | NA | NA | 1.40 (0.85–2.32) | 1.87 (1.01–3.44) | |
| GSE58812 | Q1 | Ref. | Ref. | Ref. | Ref. |
| Q2 | 1.23 (0.44–3.52) | 1.37 (0.49–3.93) | 2.04 (0.78–5.93) | 2.12 (0.81–6.17) | |
| Q3 | 0.48 (0.13–1.59) | 0.59 (0.16–1.97) | 0.57 (0.15–2.00) | 0.68 (0.17–2.38) | |
| Q4 | 1.50 (0.57–4.13) | 1.90 (0.73–5.25) | 1.76 (0.65–5.19) | 2.11 (0.78–6.24) | |
| NKI | Q1 | Ref. | Ref. | Ref. | Ref. |
| Q2 | 1.45 (0.63–3.52) | 1.31 (0.56–3.21) | 1.22 (0.67–2.27) | 1.21 (0.65–2.25) | |
| Q3 | 3.70 (1.81–8.34) | 2.17 (1.02–5.04) | 2.61 (1.52–4.62) | 1.98 (1.12–3.59) | |
| Q4 | 4.23 (2.09–9.47) | 1.52 (0.67–3.74) | 2.59 (1.51–4.59) | 1.54 (0.81–2.98) | |
| Pooled analysis† | Q1 | Ref. | Ref. | Ref. | Ref. |
| Q2 | 1.33 (0.91–1.98) | 1.56 (0.97–2.57) | 1.26 (1.01–1.59) | 1.19 (0.90–1.58) | |
| Q3 | 2.01 (1.41–2.92) | 1.67 (1.05–2.72) | 1.41 (1.13–1.77) | 1.25 (0.95–1.66) | |
| Q4 | 3.10 (2.22–4.41) | 1.79 (1.12–2.96) | 1.85 (1.50–2.30) | 1.18 (0.89–1.59) | |
HR=hazard ratio; CI=confidence interval; NA=not applicable.
*For multivariate analyses, HR was adjusted by age, estrogen receptor (ER) status, and Elston grade in GSE10885, GSE25066, GSE53031, GSE22226; for GSE1456, it was adjusted by Elston grade, ER and human epidermal growth factor receptor 2 status; for GSE2034, HR was adjusted by ER status. For GSE4922 and GSE7390, HR was adjusted by age, ER, Elston grade T stage and N stage. For GSE58812, HR was adjusted by age and ER. The NKI set was adjusted by age, grade, ER, tumor size, and lymph node status; †Pooled analysis was performed with adjustment for age, grade and ER status.